Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of DYP688 monotherapy in metastatic uveal melanoma and other GNAQ/11-mutant melanomas
NL-OMON59386Phase 2Suspended
- Sponsor
- Novartis
- Start
- Nov 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of DYP688 in intraocular melanoma, cutaneous melanoma (CM) and mucosal melanoma (MM) (5 arms), sponsored by Novartis. Primary endpoints: Dose-limiting toxicities, Safety and tolerability and 2 more. Started Nov 2022; status: suspended.
02
Drugs
DYP688
03
Conditions
intraocular melanomacutaneous melanoma (CM)mucosal melanoma (MM)
Beyond the preview
Go deeper on NL-OMON59386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59386.